Banque Pictet & Cie SA Sells 2,061 Shares of Repligen Co. (NASDAQ:RGEN)

Banque Pictet & Cie SA cut its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 8.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,392 shares of the biotechnology company's stock after selling 2,061 shares during the period. Banque Pictet & Cie SA's holdings in Repligen were worth $3,223,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Blue Trust Inc. raised its stake in shares of Repligen by 113.4% during the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company's stock worth $36,000 after purchasing an additional 127 shares during the period. Resources Management Corp CT ADV purchased a new stake in shares of Repligen during the 3rd quarter worth approximately $37,000. Quarry LP lifted its stake in Repligen by 796.7% in the third quarter. Quarry LP now owns 269 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 239 shares during the last quarter. nVerses Capital LLC bought a new position in Repligen during the third quarter valued at $45,000. Finally, UMB Bank n.a. increased its position in Repligen by 49.1% in the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock worth $48,000 after buying an additional 110 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on RGEN shares. StockNews.com raised Repligen from a "sell" rating to a "hold" rating in a report on Friday, January 3rd. Wolfe Research assumed coverage on shares of Repligen in a research note on Thursday, November 14th. They issued a "peer perform" rating for the company. Canaccord Genuity Group assumed coverage on Repligen in a research report on Tuesday, December 17th. They set a "hold" rating and a $165.00 target price on the stock. TD Cowen began coverage on Repligen in a research note on Monday, February 10th. They issued a "buy" rating and a $200.00 target price for the company. Finally, HC Wainwright lowered their price target on shares of Repligen from $240.00 to $180.00 and set a "buy" rating on the stock in a report on Thursday, January 23rd. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $182.91.

Repligen Price Performance

Shares of RGEN traded down $1.74 during midday trading on Tuesday, reaching $145.18. The stock had a trading volume of 530,842 shares, compared to its average volume of 542,913. Repligen Co. has a 12-month low of $113.50 and a 12-month high of $207.87. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The company's 50-day moving average is $155.26 and its 200 day moving average is $148.82. The company has a market capitalization of $8.13 billion, a price-to-earnings ratio of -392.37, a price-to-earnings-growth ratio of 4.54 and a beta of 0.99.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.